From Approval to Clinical Practice: Advancing Ketone Monitoring for T1D
The First Dual Glucose-Ketone Monitor is Approved in the U.S. You might have seen the news: the U.S. Food and Drug Administration approved Abbott’s Libre Duo 10 Day, the world’s first dual glucose-ketone sensing technology for ages 2+. Studies have shown that many people with type 1 diabetes (T1D) don’t have ketone testing supplies at […]
From T1D Toddler to Resilient Adult: Jessie Stover Shares her Story
Spotlight on Jessie Stover Jessie Stover is the Development Manager at Breakthrough T1D’s Indiana Chapter. Stover was born and raised in Evansville, Indiana, and she now lives in Indianapolis with her two cats, Milo and Zuko. She enjoys reading, crafting, concerts, and “baking gluten-free desserts so good that no one can tell they’re gluten-free.” Here, […]
What is Time in Range?
Time in range is a metric measured by continuous glucose monitors. Learn about why it matters and future applications.
Golf Champion J.J. Spaun: A Hero Who’s One of Us
Golf champion J.J. Spaun discusses his game and life with T1D with dedicated Breakthrough T1D supporter Moira McCarthy.
Navigating issues with your continuous glucose monitor (CGM)
Breakthrough T1D created a guide for sensor issues, from what to do if symptoms and CGM reading do not match to how to get a replacement.
Support and resources for your CGM
Support and resources for issues with continuous glucose monitors (CGMs), including inaccurate readings and faulty sensors.
Special Diabetes Program yields $50+ billion in Federal healthcare savings
Analysis compiled by Avalere Health and supported by Breakthrough T1D (formerly JDRF) finds that research funded by the Special Diabetes Program (SDP) has yielded more than $50 billion in federal healthcare savings. Created by Congress in 1997 and administered by the National Institutes of Health (NIH), the SDP provides federal funding to support research to prevent, treat, and […]
Can Continuous Glucose Monitors Benefit People Without Type 1 Diabetes?
Continuous glucose monitors have been transformative for daily type 1 diabetes management. Can they benefit people without diabetes?
ADA 2025 Recap: Cures
Breakthrough T1D was in Chicago, IL for ADA 2025. Here we report on the latest advancements in cures for type 1 diabetes.
ADA 2025 Recap: Improving Lives
Improving Lives Breakthrough T1D’s Improving Lives program focuses on devices, insulins, adjunctive therapies, treatments for complications, and psychosocial interventions to improve the health and quality of life of people living with T1D. Adjunctive therapies and complications There was significant focus on GLP-1 receptor agonists (GLP-1RAs) and SGLT inhibitors (SGLTi) in reducing long-term complications and improving […]
